Critical limb ischemia (CLI) represents the most severe manifestation of peripheral arterial disease (PAD). It imposes a huge economic burden and is associated with high short-term mortality and adverse cardiovascular outcomes. Prompt recognition and early revascularization, surgical or endovascular, with the aim of improving the inline bloodflow to the ischemic limb, are currently the standard of care. However, this strategy may not always be feasible or effective; hence, evaluation of newer pharmacological or angiogenic therapies for alleviating the symptoms of this alarming condition is of utmost importance. Cell-based therapies have shown promise in smaller studies; however, large-scale studies, demonstrating definite survival benefits, are entailed to ascertain their role in the management of CLI.
Introduction
Critical limb ischemia (CLI) represents the most severe and probably an end-stage manifestation of peripheral arterial disease (PAD) and is still considered an orphan disease with no effective medical treatment. It constitutes a considerable social and economic burden and is associated with a dismal prognosis. CLI may develop from many fundamentally distinct pathophysiological processes, including, more commonly, advanced atherosclerosis and, less commonly, thromboembolism, in situ thrombosis, and the arthritides. It is associated with high short-term mortality, as well as adverse cardiovascular events. [1, 2] Revascularization, wherever feasible, is the cornerstone of therapy; however, major amputations and death remain the most frequent complications. Considerable major amputation rates in the range of 10-40% have been seen in these patients, particularly with failed revascularization or in those with "no-option" CLI. [3] [4] [5] Exploring newer approaches for revascularization of these ischemic limbs is therefore of prime importance. Cell-based therapies have come into view as a new frontier in this direction and bone marrow-derived stem cells (BM-SC) are currently seen as a prospective and possible newer therapeutic option in this regard.
Therapeutic Angiogenesis
Therapeutic angiogenesis with BM-SC or progenitor cells is currently being explored in the management of CLI with great enthusiasm because of promising early results in various preclinical trials. Clinical benefits reported from the use of stem cells in these studies include improvement in the ankle-brachial index (ABI), transcutaneous partial pressure of oxygen (TcPO 2 ), reduction of pain, and reduced rates of limb amputation. Ongoing research pertains to the cell isolation method, suitable cell source, optimal cell type, right dosage, administration route, and identification of optimal measures of outcomes for these therapies.
Stem cells have tremendous potential to differentiate and evolve into differentiated cell types. Whenever the stem cell divides, each newer cell can remain as a stem cell or develop into a different cell type with a highly specialized function. The majority of cell-based therapies in experimental or clinical use generally include embryonic stem cells, cord blood cells, cells from the blastocysts, or the adult stem cells. The stem cells gradually get stimulated by the surrounding cellular environment (damaged hypoxic tissues) that leads to the formation of specialized cells identical to those they come in contact and grow with. Paracrine effects mediated by the release of various factors (cytokines, chemokines, and growth factors) are largely responsible for these reparative processes, particularly neoangiogenesis [ Figure 1 ]. By the virtue of this, these cells are able to become newer blood vessels, BM, neurons, pancreas, etc., depending upon the local tissue characteristics and milieu. The safety and efficacy of endovascular delivery of these BM-SC have been evaluated in various studies in the treatment of patients with chronic disease states, such as CLI, diabetes mellitus (DM), chronic renal failure, cerebral palsy (CP), muscle dystrophy (MD), spinal cord injury, and dilated cardiomyopathy (DCM). [6] [7] [8] [9] [10] [11] 
Stem cell retrieval and injection
BM aspiration from the posterior iliac crest is usually preferred in adult patients as it is readily accessible, safe, and less traumatic. [12] Moreover, it usually yields adequate representative sample. Other sites may include the sternum, vertebral spine, and anterior iliac crest. Separation and injection of stem cells are usually preferred on the day of aspiration. These cells may be injected intramuscularly (IM) or intraarterially (IA) or using the combined IM/IA route. The stem cell injection with a predetermined dose is usually targeted at the disease site, such as occluded vascular segment in CLI, the pancreaticoduodenal artery in DM, spinal artery in cord injury, extremity artery in MD, coronary artery in cases of DCM, and internal carotid artery in CP patients. Follow-up may be done at 1, 3, and 6 months and annually thereafter with preset endpoints depending on the initial indication. These endpoints may include ulcer healing, rest pain relief, improvement in claudication free walking distance, enhancement of collaterals formation on imaging, and upgradation of quality of life (QOL) in CLI patients.
Effectiveness of therapy
Many studies have shown the effectiveness of stem cell therapy in CLI patients, including randomized trials, nonrandomized trials, and noncontrolled studies. However, owing to the heterogeneity among various studies, limited sample sizes and lack of large-scale placebo-controlled studies, acceptance of this mode of therapy as the standard of care is still a matter of debate. Transplantation of autologous BM-SC has also been evaluated in terms of different approaches for the implantation, viz. IM injection, IA injection, or combined, and has shown nearly similar results in this aspect. [13] BM stimulation using an injection of the recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has also shown to be advantageous in terms of higher concentration of mononuclear cells (MCs) requiring lesser aspirations with satisfactory short-term effects. [14] Moreover, a comparative study on autologous injection using peripheral blood stem cells (PB-SCs) or BM-SC has also shown similar efficacy in treating lower limb ischemia. [15] The first substantial report using IM autologous BM-MCs in limb ischemia came from the Therapeutic Angiogenesis Using Cell Transplantation (TACT) study. The study showed a 60% (95% confidence interval [CI], 46-74) 3-year amputation-free rate; and significant improvement in the clinical assessments of leg pain, ulcer size, and claudication free walking distance, which was sustained till at least 2 years after the therapy, although the change in the objective parameters of ABI and TcPO 2 was not statistically significant. [16] Bone Marrow Outcomes Trial 1 (BONMOT-1) demonstrated an increase in leg perfusion with a reduction in amputation rates in 51 "no-option" CLI patients transplanted IM with autologous BM cells into the ischemic leg. [17] 59% and 53% of the limbs were salvaged at 6 months and at the last follow-up (range 175-1186 days) respectively, with increase in ABI (0.33 ± 0.18 to 0.46 ± 0.15) and TcPO 2 (12 ± 12 to 25 ± 15 mm Hg) noted at 6 months. The mean Rutherford category improved from 4.9 (baseline) to 3.3 (6 months) using P = 0.0001, with the reduction in the analgesic consumption by 62% and improvement in total walking distance from 0 to 40 m. In both the BONMOT-1 and BONMOT-CLI, which was an ensuing double-blind placebo-controlled trial, the BM-MNC injections were given along the anatomic course of the occluded arteries. This maximizes their impact as the density of the preexisting collaterals is presumed to be highest in these regions. [18] Moreover, in the BONMOT-1 and BONMOT-CLI, the length of the occlusion determined the number of such injections.
The RESTORE-CLI trial of 77 lower limb CLI patients compared IM injection of ixmyelocel-T (patient-specific, expanded, and multicellular therapy) to placebo. [19] The trial showed significant improvement in the time duration of first treatment failure (P = 0.0032, logrank test). Although there was a 32% decrease in amputation-free survival, this result was not statistically significant (P = 0.3). The effect of treatment in those with wounds at baseline was more marked. [19] The interim analysis of the HARVEST trial also showed an improving trend in the control of major amputations, pain improvement, QOL score, ABI, and Rutherford classification in the BM aspirate concentrate group as compared with the controls. [20] The PROVASA trial (randomized-start, placebo-controlled pilot trial) randomized 40 patients with CLI to IA delivery of either BM-MNC or placebo followed by active treatment at 3 months with BM-MNC. [21] Though the study showed significant improvement in rest pain and ulcer healing in the BM-MNC group, patients with gangrene or considerable tissue loss at baseline were nonresponders. Another relevant conclusion from the study was that multiple treatments were more effective than a single treatment. From the therapy perspective, a higher number of BM-MNC delivered with repeated administration and greater functionality predicted ulcer healing.
No treatment-related adverse reactions were noted in another study that compared combined IM and IA (n = 15) delivery of autologous BM-MNC with exclusive IM (n = 12) injections in patients with CLI. [22] Although only two patients in the combined group versus seven patients in the IM group needed amputation, the difference was not statistically significant (P = 0.17). Sustained significant improvement in clinical and objective parameters was seen in rest of the patients during follow-up. The transplantation of autologous mononuclear BM stem cells in patients with peripheral arterial disease (TAM-PAD) study has also shown similar results. [23] However, similar results are seen in another study comparing the mode of implantation of stem cells with no statistically significant difference. [13] Various preclinical studies have shown the role of stromal-cell derived factor-1 (SDF-1) in promoting tissue repair via mechanisms involving neoangiogenesis and stem-cell repair pathways, thus, preventing on-going cell death. [24, 25] A phase II clinical trial (JUVENTUS) has been approved to evaluate its safety and efficacy in the treatment of CLI patients.
Other studies evaluating the role of stem cells in CLI patients have been enumerated in Table 1 . [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] The latest meta-analysis (19 randomized controlled trials [RCTs], 7 nonrandomized trials, and 41 noncontrolled studies) has shown that autologous cell therapy has the potential to favorably alter the natural history of intractable CLI with better composite clinical outcome, avoidance of amputations, and thus improvement in the QOL. [44] It showed a 37% reduction in the risk of amputation, 18% improvement in amputation-free survival, and 59% improved wound healing and reduction in rest pain without affecting mortality. Moreover, cell therapy has also shown a significant increase in objective indices like ABI and TcPO 2 . In this analysis, IM implantation fared better than IA infusion and mobilized peripheral blood MNCs (PB-MNCs) were more effective than BM-MNCs and mesenchymal stem cells.
In another meta-analysis, amputation reduction (nearly 60%) and improvement in ulcer healing, ABI, TcO2, pain-free walking capacity, and collateralization have been shown with moderate quality of evidence in patients receiving cell-based therapy compared to those receiving noncell-based therapy with similar all-cause mortality rates (high-quality evidence) noted between the two groups. [45] A meta-analysis of database until January 2018 also demonstrated the effectiveness of cell therapy with significantly increased probability of ulcer healing and angiogenesis with reduced amputation rates. ABI, TcPO 2 , and pain-free walking distance were significantly better in the cell therapy group than in the control group (P < 0.01). [46] Further, no clear differences have been shown between different stem cell sources, treatment regimens, doses, and routes of administration in terms of outcomes, such as all-cause mortality, amputation rate, ulcer healing, and rest pain for "no-option" CLI patients. [47] However, high-quality 
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Significant changes in the treatment group
Huang et al. [26] (2005) IM G-CSF and PB-MNCs CLI of diabetic patients RCT 28 3 Improvement in ABI, angiographic score, and ulcer healing compared with the control group. No amputation vs 5/14 in the control group.
Arai et al. [27] ( Barć et al. [28] Lu et al. [29] (2008) IM BM-MSCs Lower limb ischemia in Type 2 diabetes RCT 50 3
Ulcer healing rate and ABI more in the treatment group Amputation rate lower.
Dash et al. [30] (2009)
IM BM-MSCs Nonhealing ulcers (Diabetes and Buergers)
RCT 24 3 Improvement in pain-free walking distance and reduction in ulcer size.
Procházka et al. [31] (2010) IA BM-SCs CLI patients with foot ulcer RCT 96 4
Reduced major amputation rate and improvement in toe brachial index and toe pressure in salvaged limbs of the treatment group.
Wen and Huang [32] (2010) IM PB-SCs CLI RCT 60 3 Improvement in ABI, ulcer healing, and angiographic scores and lower amputation rates in the treatment group.
Lu et al. [33] (2011) IM BM-MSC vs BM-MNC Type 2 diabetes with bilateral CLI BM-MSC or BM-MNC or normal saline 41 6 Ulcer healing rate; pain-free walking distance; and ABI, TCPO2, and angiographic score of BM-MSC higher than BM-MNC. No difference in pain relief or amputation rate.
Jain et al. [34] 
Topically applied and locally injected BM-SC vs whole blood (control)
Diabetes with chronic ulcer RCT 48 3
Increased rate of ulcer healing in the treatment group.
Benoit et al. [35] (2011)
IM BM-SCs vs peripheral blood (placebo)
No option CLI Double-blinded pilot RCT  48  6 Lower amputation rates and longer time to amputation in the treatment group.
Losordo et al. [36] (2012)
IM CD34+
Nonrevascularisable CLI RCT 28 patients to 7 to 1 × 105 (low-dose) and 9-1 × 106 (high-dose) autologous CD34+ cells/kg; and 12 to placebo 40 12 Major and minor amputation rates lowest in the high dose treatment group.
Ozturk et al. [37] (2012) G-CSF mobilized PB-MNCs delivered IM Diabetes with CLI RCT 40 3 Improvement in the Fontaine score, ABI, TCPO2, and 6 min walking distance. A decrease in the pain score and number of ulcers.
Gupta et al. [38] 
IM allogeneic BM-MSCs CLI Double-blinded, randomized, placebo-controlled multicenter study 20 6 Improvement in pain score, ABI, and ankle pressure in the treatment group. Serious adverse events similar in both groups.
Li et al. [39] (2013) IM BM-MNCs CLI RCT 58 6 Improvement in rest pain, skin ulcers, and ABI.
Mohammadzadeh et al. [40] (2013) G-CSF mobilised PB-MNCs delivered IM Diabetes with CLI RCT 21 3 Improvement in pain, wound healing, and ABI, and lower amputation rates.
Szabo et al. [41] (2013)
IM In vitro expanded PB-SCs
No option for patients with peripheral arterial disease RCT 20 3 Improvement in hemodynamic parameters. No deaths or major amputation in the treatment group.
Raval et al. [42] 
IM cytokine mobilized CD133+ CLI Double-blinded, randomized, sham-controlled trial 10 12 Trends toward improved amputation-free survival, 6-minute walk distance, walking, and QOL.
Contd... evidence is still lacking and needs further substation by larger, long-term studies.
Challenges and limitations of stem cell therapy
Despite encouraging results from multiple studies, many questions and challenges remain unanswered with regard to stem cell therapy, including the exact understanding of the precise molecular mechanisms of the therapy and the identification of the ideal cell type, optimal dosage, route, and frequency of administration. Moreover, we must expand our understanding regarding various tissue endogenous microenvironmental factors, which may affect the in situ differentiation or therapeutic activity of the applied stem cells. Effective and large-scale protocols regarding in vitro cell differentiation need to be established in addition to various efficient methods for augmentation of cell potency, which may include ex vivo stimulation of the stem cells with cytokines and various growth factors, such as hepatocyte and fibroblast growth factor (FGF), SDF-1α, and granulocyte-colony stimulating factor (G-CSF). [48] [49] [50] [51] [52] Also, the role of autologous versus allogeneic stem cell therapy in CLI needs to be addressed to develop more effective methods to manipulate therapeutic arteriogenesis. [53, 54] 
Future directions
Overall, the stem cell-based therapy has shown to be safe and effective with mild and, mostly, transient-associated adverse reactions, commonly related to local implantation/ injection. Further, the use of preconditioning strategies and sustained release of growth factors via the use of bioactive microspheres may enhance the therapeutic efficacy of cell therapy. Considering the fact that a significant number of patients with CLI may not be a candidate for revascularization, stem cell-based therapy may be a potential candidate as a standard of care as it seems to have the potential to alter the natural history of CLI.
Conclusion
Autologous stem cell therapy is evolving as a promising newer tool in the management of CLI. Initial evidence is supportive of its safety, feasibility, and effectiveness of many important endpoints. However, the acceptance of this mode of therapy as a standard of care is still a matter of debate as its efficacy is not consistent when analyzing only the placebo-controlled randomized trials. Further, large studies meeting important endpoints with definite survival benefit are required to establish its role in the management of CLI.
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Study (Year) Cell type and route of injection
Broad inclusion criteria
Type of study Sample size
Duration of follow up (Months)
Significant changes in the treatment group
Skóra et al. [43] (2015)
Autologous BM-MNC and  VEGF plasmid vs  pentoxifylline   CLI  RCT  32  3 Significant improvement in ABI, collateralization, ulcer healing. Lower rate of amputation.
CLI=Critical limb ischemia, IM=Intramuscular, G-CSF=Granulocyte-colony stimulating factor, PB-MNCs=Peripheral blood mononuclear cells, RCT=Randomized controlled trial, ABI=Ankle-brachial index, QOL=Quality of life, BM-MNCs=Bone marrow mononuclear cells, PAD=Peripheral arterial disease, GDMT=Guideline-directed management and therapy, TcPO2=Transcutaneous partial pressure of oxygen, BM-MSCs=Bone marrow mesenchymal stem cells, IA=Intramuscular, BMSCs=Bone marrow stem cells, PB-SCs=Peripheral blood stem cells, VEGF=Vascular endothelial growth factor
